Spotlight Focus: Unwanted immunogenicity of immune-oncology drugs with MHRA, EpiVax, Roche, Novartis, AbbVie & many more - PR News

Press Release Distribution Service

Latest News from PR Log

Agriculture - Latest News

Automotive - Latest News

Biotech - Latest News

Computers - Latest News

Deals - Latest News

Defense - Latest News

Education - Latest News

Tuesday 21 March 2017

Spotlight Focus: Unwanted immunogenicity of immune-oncology drugs with MHRA, EpiVax, Roche, Novartis, AbbVie & many more

SMi's 4th annual Immunogenicity Conference addressing clinical excellence of biotherapeutics through regulation and advanced immunogenicity assessments

No comments:

Post a Comment

Electronics - Latest News